ATAI Life Sciences is trading 45.1% up today at $7.78 following reports that Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic drug developer linked to the company.
- The potential acquisition is reportedly being negotiated at a premium to AtaiBeckley's estimated $2 billion market value.
- A formal announcement could be made as early as this week, driving strong demand as investors price in a strategic M&A premium.